| Literature DB >> 32646198 |
Ajit Sood1, Vineet Ahuja2, Vandana Midha3, Saroj Kant Sinha4, C Ganesh Pai5, Saurabh Kedia2, Varun Mehta1, Sawan Bopanna6, Philip Abraham7, Rupa Banerjee8, Shobna Bhatia9, Karmabir Chakravartty10, Sunil Dadhich11, Devendra Desai7, Manisha Dwivedi12, Bhabhadev Goswami13, Kirandeep Kaur14, Rajeev Khosla15, Ajay Kumar16, Ramit Mahajan1, S P Misra12, Kiran Peddi17, Shivaram Prasad Singh18, Arshdeep Singh1.
Abstract
Despite several recent advances in therapy in inflammatory bowel disease (IBD), 5-aminosalicylic acid (5-ASA) therapy has retained its place especially in ulcerative colitis. This consensus on 5-ASA is obtained through a modified Delphi process, and includes guiding statements and recommendations based on literature evidence (randomized trials, and observational studies), clinical practice, and expert opinion on use of 5-ASA in IBD by Indian gastroenterologists. The aim is to aid practitioners in selecting appropriate treatment strategies and facilitate optimal use of 5-ASA in patients with IBD.Entities:
Keywords: 5-Aminosalicylic acid; Colitis, ulcerative; Crohn disease; Inflammatory bowel disease; Mesalamine
Year: 2020 PMID： 32646198 DOI： 10.5217/ir.2019.09176
Source DB: PubMed Journal: Intest Res ISSN： 1598-9100